Objectives: Endometrial cancer with peritoneal metastases may have similar biology to other cancers that respond to treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). We present our experience and provide an extensive literature review of endometrial cancer treated with CRS/HIPEC. Methods: A review of a single-institution prospective database of 949 CRS/HIPEC patients and the English literature in PubMed was performed to identify cases of peritoneal metastases from endometrial origin treated with CRS/HIPEC. Perioperative variables and outcomes were analyzed. Patients at our center were selected for CRS/HIPEC based on feasibility of obtaining a complete cytoreduction (CC) (residual disease Results: Endometrial cancer was identified in 16 patients from 1994-2020. Three cases (19%) were aborted due to inability to achieve a CC. Of the 13 patients treated with CRS/HIPEC, histopathologic subtypes included 6 (46%) endometrioid adenocarcinomas, 4 (31%) endometrial carcinosarcomas, 2 (15%) mixed endometrioid/serous adenocarcinomas, and 1 (8%) clear cell carcinoma. Median age at CRS/HIPEC was 63 years (IQR: 53-66; range: 44-72). Seven (54%) underwent CRS/HIPEC as initial treatment and 6 (46%) underwent CRS/HIPEC for recurrence. Median PCI was 15 (IQR: 6-24; range: 3-36) with CC achieved in 12 (92%). Median hospital stay was 10 days (IQR: 8-11; range: 6-15). Only 1 (7%) grade III complication and no grade IV/V complications occurred. Adjuvant chemotherapy was administered in 5 (38%) patients. After median follow-up of 56.4 months (CI95% 49.0-63.8; range: 18.7-85.2), median overall (OS) and progression-free survival (PFS) were 33.9 and 14.4 months, respectively. Literature review revealed 8 reports with 107 cases of endometrial cancer treated with CRS/HIPEC, including 50% endometrioid adenocarcinomas, 14% serous carcinomas, 3% clear cell carcinomas, 3% carcinosarcomas, 2% mixed endometrioid/serous adenocarcinomas, 1% mesonephric, 1% squamous carcinomas, and 26% unspecified non-endometrioid adenocarcinomas. Age at HIPEC ranged from 26-73 years. Overall, 76% were treated for disease recurrence and 24% were newly diagnosed. CC was achieved in 92%. Length of hospital stay ranged from 6-90 days and 70% received adjuvant chemotherapy. Median OS and PFS ranged from 19.4-33.1 and 11.4-18 months, respectively. Conclusions: CRS/HIPEC seems to be a reasonable strategy to treat these challenging patients with PM from endometrial origin and may offer recurrence-free time off treatment in select patients whose alternative is continuous systemic therapy. Multicenter trials are indicated to evaluate survival and optimal patient selection criteria.